Document is current

Article History

Received: 17 July 2024

Accepted: 18 September 2024

First Online: 7 October 2024

Declarations

:

: This study was conducted in compliance with the guidelines of the Declaration of Helsinki, and written informed consent was obtained from all patients. The protocols for generating HLA-edited healthy donor-derived iPSCs were approved by the Ethics Committee of Center for iPS Cell Research and Application (approval number #CiRA19-03, Research on establishment of HLA-edited iPS cell stock for clinical application, approval date; 2019/June/4). Experiments involving human primary bone marrow were approved by the same committee (approval number #G1052, Establishment of evaluation criteria for regenerative medicine of musculoskeletal tissues, approval date; 2020/December/8). Experiments using human primary adipose tissue were approved by the Ethical Review Board for Clinical Studies at Nagoya University and the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine (approval number #2005–0247-8, Research of adipose-derived stem cells for clinical application, approval date; 2022/January/24). Written informed consent was obtained from all donors of iPSCs, adipose tissue, and bone marrow used in this study. All animal experiments were conducted according to protocols approved by the Animal Research Committee of Kyoto University (approval number #21–146, Research on the induction of mesenchymal progenitor cells from human induced pluripotent stem cells and their transplantation therapy for refractory muscle disorders, approval date: 2021/April/1).

: Not applicable.

: The authors declare that they have no competing interests.